CPT® Code 82234

The CPT® Code 82234 refers to the measurement of beta-amyloid 1-42 (Abeta 42), a peptide that plays a significant role in the pathology of Alzheimer's disease. Beta-amyloid is recognized as a critical factor in the development of this neurodegenerative condition, with its abnormal accumulation in the brain being one of the earliest changes that can occur, potentially up to 20 years prior to the manifestation of clinical symptoms. The presence of beta-amyloid plaques is associated with neuronal death and synaptic loss, which ultimately leads to cognitive impairment and, subsequently, dementia. The assessment of beta-amyloid levels, specifically Abeta 40 and Abeta 42, serves as a biomarker test for individuals experiencing cognitive decline. This testing is instrumental in the early diagnosis of Alzheimer's disease, allowing healthcare providers to differentiate it from other cognitive disorders or normal aging processes. Furthermore, it aids in the timely initiation of treatment strategies. Various commercial blood biomarker tests are available for this purpose, and cerebrospinal fluid analysis may also be utilized. Notably, an increase in beta-amyloid 1-40 levels is strongly linked to Alzheimer's disease, while a decrease in the normal ratio of beta-amyloid 42 to 40 (specifically below 0.073) serves as a significant early indicator of the disease, detectable even before dementia symptoms arise.